J Korean Med Assoc.  2015 Sep;58(9):818-824. 10.5124/jkma.2015.58.9.818.

Type and treatment of toxic mushroom poisoning in Korea

• Sohn CH

• KMID: 2195095
• DOI: http://doi.org/10.5124/jkma.2015.58.9.818

Abstract

To eat unidentified or misidentified mushrooms taken from the wild can be very dangerous. In the vast majority of toxic mushroom ingestions in Korea, the mushroom was incorrectly identified. In general, poisoning of toxic mushrooms can be classified into seven types according to the toxins that they contain; amatoxin, gyromitrin, coprine, muscarine, ibotenic acid-muscimol, psilocybin-psilocin and gastrointestinal irritants. When clinicians care for a patient who ingested a toxic mushroom, it is very important to identify what kind of mushroom may have caused a patient's illness. But, in clinical practice, accurate botanical identification of the mushroom can be very difficult. Therefore, for estimating the caused mushroom and adequate treatment of poisoning, clinicians should know the type and treatment of toxic mushroom poisoning.

Keyword

Mushroom; Poisoning; Toxin; Therapeutics

MeSH Terms

Agaricales*
Edetic Acid
Humans
Irritants
Korea*
Muscarine
Mushroom Poisoning*
Poisoning
Edetic Acid
Irritants
Muscarine

Reference

1. Korea Forest Research Institute. National Academy of Agricultural Science. Poisonous mushroom in the woods. Seoul: Korea Forest Research Institute;2014.

2. Seok SJ, Kim YS, Kim WG, Suh JS, Jeong MH, Lim KS, Sohn CH, Lee YS. Encyclopedia of poisonous mushrooms. Seoul: Blue Happiness Press;2011.

3. Auerbach PS. Wilderness medicine. 6th ed. Edinburgh: Mosby;2011.

4. Fantozzi R, Ledda F, Caramelli L, Moroni F, Blandina P, Masini E, Botti P, Peruzzi S, Zorn M, Mannaioni PF. Clinical findings and follow-up evaluation of an outbreak of mushroom poisoning: survey of Amanita phalloides poisoning. Klin Wochenschr. 1986; 64:38–43.

5. Busi C, Fiume L, Costantino D, Langer M, Vesconi F. Amanita toxins in gastroduodenal fluid of patients poisoned by the mushroom, Amanita phalloides. N Engl J Med. 1979; 300:800.

6. Garrouste C, Hemery M, Boudat AM, Kamar N. Amanita phalloides poisoning-induced end-stage renal failure. Clin Nephrol. 2009; 71:571–574.

7. Kelner MJ, Alexander NM. Endocrine hormone abnormalities in Amanita poisoning. J Toxicol Clin Toxicol. 1987; 25:21–37.

8. Sanz P, Reig R, Borras L, Martinez J, Manez R, Corbella J. Disseminated intravascular coagulation and mesenteric ven-ous thrombosis in fatal Amanita poisoning. Hum Toxicol. 1988; 7:199–201.

9. Floersheim GL, Weber O, Tschumi P, Ulbrich M. Clinical death-cap (Amanita phalloides) poisoning: prognostic factors and therapeutic measures: analysis of 205 cases. Schweiz Med Wochenschr. 1982; 112:1164–1177.

10. Faulstich H. New aspects of amanita poisoning. Klin Wochenschr. 1979; 57:1143–1152.

11. Hoffman RS, Howland MA, Lewin NA, Nelson L, Goldfrank LR. Goldfrank's toxicologic emergencies. 10th ed. New York: McGraw-Hill Education;2015.

12. Piqueras J, Duran-Suarez JR, Massuet L, Hernandez-Sanchez JM. Mushroom poisoning: therapeutic apheresis or forced diuresis. Transfusion. 1987; 27:116–117.

13. Enjalbert F, Rapior S, Nouguier-Soule J, Guillon S, Amouroux N, Cabot C. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol. 2002; 40:715–757.

14. Erffmeyer JE. Adverse reactions to penicillin. Part I. Ann Allergy. 1981; 47:288–293.

15. Neftel KA, Hauser SP, Muller MR. Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics. J Infect Dis. 1985; 152:90–98.

16. Laekeman G, De Coster S, De Meyer K. St. Mary's Thistle: an overview. J Pharm Belg. 2003; 58:28–31.

17. Ramellini G, Meldolesi J. Liver protection by silymarin: in vitro effect ondissociated rat hepatocytes. Arzneimittelforschung. 1976; 26:69–73.

18. Vogel G, Trost W, Braatz R, Odenthal KP, Brusewitz G. Studies on pharmacodynamics, site and mechanism of action of silymarin, the anti-hepatotoxic principle from Silybum marianum (L.). Arzneimittelforschung. 1975; 25:179–188.

19. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998; 93:139–143.

20. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs. 2001; 15:465–489.

21. Floersheim GL. Treatment of mushroom poisoning. JAMA. 1985; 253:3252.

22. Schneider SM, Borochovitz D, Krenzelok EP. Cimetidine protection against alpha-amanitin hepatotoxicity in mice: a potential model for the treatment of Amanita phalloides poisoning. Ann Emerg Med. 1987; 16:1136–1140.

23. Vanscoy GJ, Schneider SM. Cimetidine and ascorbic-acid in the treatment of alpha-amanitin toxicity in mice. Vet Hum Toxicol. 1988; 30:368.

24. Azar A, Thomas AA, Shillito FH. Pyridoxine and phenobarbital as treatment for aerozine-50 toxicity. Aerosp Med. 1970; 41:1–4.

25. Klosterman HJ. Vitamin B6 antagonists of natural origin. J Agric Food Chem. 1974; 22:13–16.

26. Lincoff G, Mitchel DH, Liberman IE. Toxic and hallucinogenic mushroom poisoning: a handbook for physicians and mushroom hunters. New York: Van Nostrand Reinhold;1977.

27. Honegger P, Pardo B, Monnet-Tschudi F. Muscimol-induced death of GABAergic neurons in rat brain aggregating cell cultures. Brain Res Dev Brain Res. 1998; 105:219–225.

28. Gilad E, Biger Y. Paralysis of convergence caused by mushroom poisoning. Am J Ophthalmol. 1986; 102:124–125.

29. Mendelson G. Treatment of hallucinogenic-plant toxicity. Ann Intern Med. 1976; 85:126.

30. Satora L, Pach D, Ciszowski K, Winnik L. Panther cap Amanita pantherina poisoning case report and review. Toxicon. 2006; 47:605–607.

31. Pauli JL, Foot CL. Fatal muscarinic syndrome after eating wild mushrooms. Med J Aust. 2005; 182:294–295.

32. Peden NR, Pringle SD, Crooks J. The problem of psilocybin mushroom abuse. Hum Toxicol. 1982; 1:417–424.

33. Mccawley EL, Brummett RE, Dana GW. Convulsions from psilocybe mushroom poisoning. Proc West Pharmacol Soc. 1962; 5:27–33.